In an interview with ONCOLOGY®, Evan B. Bryson, PharmD, BCOP, offers a comprehensive review of real-world treatment considerations of amivantamab as therapy for patients with non–small cell lung cancer.
Evan B. Bryson, PharmD, BCOP
Advertisement
Articles by Evan B. Bryson, PharmD, BCOP
Advertisement
Latest Updated Articles
Expert Commentary on the Product Profile of Amivantamab-vmjwPublished: March 12th 2022 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
ESMO 2025: Key Anticipated Updates in Breast and Lung Tumors
2
Adjuvant Chemotherapy Improves Long-Term Survival in Endometrial Cancer
3
Bridging Radiotherapy Prior to CAR T May Be Safe in R/R Multiple Myeloma
4
Anti-TIGIT Combination Therapy Yields Positive Survival in Gastric Cancers
5
